Well so far their only costs are legal fees ...they can't be sued for damages if Amarin prevails.
If Dr Reddy prevailed whats to stop them from securing an API contract with BASF ...which can produce the API ( see previous post ) and as far as I know are not bound by a supply agreement with AMRN
If the main API suppliers are tied up by both AMRN and Dr Reddy ...then its not an open free for all until other API suppliers come on line JMO Kiwi
bio. as a follow up . As per the Teva settlement with AMRN ...they can enter if another generic prevails in any patent challenge . The key then will be who can lock up the remaining large API suppliers via supply exclusivity agreements Kiwi
Market Data 
Markets 
AI
